Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Anaesthesia ; 73(5): 631-641, 2018 May.
Article in English | MEDLINE | ID: mdl-29280475

ABSTRACT

We compared the efficacy and safety of sugammadex and neostigmine in reversing neuromuscular blockade in adults. Our outcomes were: recovery time from second twitch to train-of-four ratio > 0.9; recovery time from post-tetanic count 1-5 to train-of-four ratio > 0.9; and risk of composite adverse and serious adverse events. We searched for randomised clinical trials irrespective of publication status and date, blinding status, outcomes reported or language. We included 41 studies with 4206 participants. Time to reversal of neuromuscular blockade from second twitch to a train-of-four ratio > 0.9 was 2.0 min with sugammadex 2 mg.kg-1 and 12.9 min with neostigmine 0.05 mg.kg-1 , with a mean difference (MD) (95%CI)) of 10.2 (8.5-12.0) (I2  = 84%, 10 studies, n = 835, Grades of Recommendation, Assessment, Development and Evaluation (GRADE): moderate quality). Time to reversal of neuromuscular blockade from a post-tetanic count of 1-5 to a train-of-four ratio > 0.9 was 2.9 min with sugammadex 4 mg.kg-1 and 48.8 min with neostigmine 0.07 mg.kg-1 , with a MD (95%CI) of 45.8 (39.4-52.2) (I2  = 0%, 2 studies, n = 114, GRADE: low quality). There were significantly fewer composite adverse events in the sugammadex group compared with neostigmine, with a risk ratio (95%CI) of 0.60 (0.49-0.74) (I2  = 40%, 28 studies, n = 2298, number needed to treat (NNT): 8, GRADE: moderate quality). Specifically, the risk of bradycardia (RR (95%CI) 0.16 (0.07-0.34), n = 1218, NNT: 14, GRADE: moderate quality), postoperative nausea and vomiting (RR (95%CI) 0.52 (0.28-0.97), n = 389, NNT: 16, GRADE: low quality) and overall signs of postoperative residual paralysis (RR (95%CI) 0.40 (0.28-0.57), n = 1474, NNT: 13, GRADE: moderate quality) were all reduced. There was no significant difference regarding the risk of serious adverse events (RR 0.54, 95%CI 0.13-2.25, I2  = 0%, n = 959, GRADE: low quality). Sugammadex reverses neuromuscular blockade more rapidly than neostigmine and is associated with fewer adverse events.


Subject(s)
Neostigmine/adverse effects , Neostigmine/therapeutic use , Neuromuscular Blockade/methods , Sugammadex/adverse effects , Sugammadex/therapeutic use , Adult , Clinical Trials as Topic , Humans , Neuromuscular Blockade/adverse effects
2.
Br J Surg ; 103(12): 1676-1682, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27537860

ABSTRACT

BACKGROUND: Perforated gastroduodenal ulcer carries a high mortality rate. Need for reintervention after surgical repair is associated with worse outcome, but knowledge on risk factors for reintervention is limited. The aim was to identify prognostic risk factors for reintervention after perforated gastroduodenal ulcer in a nationwide cohort. METHODS: All patients treated surgically for perforated gastroduodenal ulcer in Denmark between 2003 and 2014 were included using data from the Danish Clinical Register of Emergency Surgery. Potential risk factors for reintervention were assessed, and their crude and adjusted associations calculated by the competing risks subdistribution hazards approach. RESULTS: A total of 4086 patients underwent surgery for perforated gastroduodenal ulcer during the study interval. Median age was 71·1 (i.q.r. 59·6-81·0) years and the overall 90-day mortality rate was 30·8 per cent (1258 of 4086). Independent risk factors for reintervention were: male sex (adjusted hazard ratio (HR) 1·46, 95 per cent c.i. 1·20 to 1·78), in-hospital perforation (adjusted HR 1·36, 1·11 to 1·68), high BMI (adjusted HR 1·49, 1·10 to 2·01), high ASA physical status grade (adjusted HR 1·54, 1·23 to 1·94), shock on admission (adjusted HR 1·40, 1·13 to 1·74), surgical delay (adjusted HR 1·07, 1·02 to 1·14) and other co-morbidity (adjusted HR 1·24, 1·02 to 1·51). Preadmission use of steroids (adjusted HR 0·59, 0·41 to 0·84) and age above 70 years (adjusted HR 0·72, 0·59 to 0·89) were associated with a reduced risk of reoperation. CONCLUSION: Obese men with coexisting diseases and high disease severity who have surgery for gastroduodenal perforation are at increased risk of reoperation.


Subject(s)
Duodenal Ulcer/surgery , Peptic Ulcer Perforation/surgery , Stomach Ulcer/surgery , Age Distribution , Aged , Aged, 80 and over , Denmark/epidemiology , Duodenal Ulcer/complications , Duodenal Ulcer/mortality , Female , Humans , Male , Middle Aged , Obesity/complications , Obesity/mortality , Peptic Ulcer Perforation/complications , Peptic Ulcer Perforation/mortality , Postoperative Complications/epidemiology , Postoperative Complications/surgery , Prospective Studies , Reoperation/statistics & numerical data , Risk Factors , Sample Size , Steroids/therapeutic use , Stomach Ulcer/complications , Stomach Ulcer/mortality , Treatment Outcome
3.
Acta Anaesthesiol Scand ; 59(6): 698-709, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25683770

ABSTRACT

BACKGROUND: Traumatic rib fractures are a common condition associated with considerable morbidity and mortality. Observational studies have suggested improved outcome in patients receiving continuous epidural analgesia (CEA). The aim of the present systematic review of randomised controlled trials (RCTs) was to assess the benefit and harm of CEA compared with other analgesic interventions in patients with traumatic rib fractures. METHODS: We performed a systematic review with meta-analysis and trial sequential analysis (TSA). Eligible trials were RCTs comparing CEA with other analgesic interventions in patients with traumatic rib fractures. Cumulative relative risks (RRs) and mean differences (MDs) with 95% confidence intervals (CIs) were estimated, and risk of systematic and random errors was assessed. The predefined primary outcome measures were mortality, pneumonia and duration of mechanical ventilation. RESULTS: A total of six trials (n = 223) were included; all were judged as having a high risk of bias. In the conventional meta-analyses, there was no statistically significant difference in mortality (RR 2.18, 95% CI 0.21-22.42; P = 0.51; I(2) = 0%), duration of mechanical ventilation (MD -7.53, 95% CI -16.32 to 1.26; P = 0.09; I(2) = 91%) or pneumonia (RR 0.49, 95% CI 0.19-1.25; P = 0.13; I(2) = 0%) between CEA and other analgesic interventions. Subgroup analyses and sensitivity analyses, including TSA confirmed the results. CONCLUSION: The quality and quantity of evidence for the use of CEA in patients with traumatic rib fractures is low, and there is no firm evidence for benefit or harm of CEA compared with other analgesic interventions. Well-powered RCTs with low risk of bias reporting clinically relevant patient-centred outcome measures are needed.


Subject(s)
Analgesia, Epidural , Pain/drug therapy , Pain/etiology , Randomized Controlled Trials as Topic , Rib Fractures/complications , Humans , Pneumonia/complications , Respiration, Artificial/statistics & numerical data
4.
Chest ; 105(5): 1604-5, 1994 May.
Article in English | MEDLINE | ID: mdl-8181373

ABSTRACT

Contrast echocardiography produced by peripheral injection of agitated saline solution is widely used for detecting intracardiac and intrathoracic extracardiac shunts, like pulmonary arteriovenous malformation (PAVM). Currently, localization of PAVM requires pulmonary angiography even after detection by computed tomography of the chest. Pulsed Doppler along with contrast echocardiography of the pulmonary veins performed during transesophageal echocardiography may aid in the localization of PAVM and in its diagnosis.


Subject(s)
Arteriovenous Malformations/diagnostic imaging , Echocardiography, Transesophageal , Pulmonary Artery/abnormalities , Pulmonary Veins/abnormalities , Aged , Contrast Media , Echocardiography , Echocardiography, Doppler , Female , Humans , Pulmonary Artery/diagnostic imaging , Pulmonary Veins/diagnostic imaging
5.
Clin Toxicol (Phila) ; 52(5): 498-505, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24815546

ABSTRACT

CONTEXT: Coating products are widely used for making surfaces water and dirt repellent. However, on several occasions the use of these products has been associated with lung toxicity. OBJECTIVE: In the present study, we evaluated the toxic effects of an aerosolized tile-coating product. METHODS: Thirty-nine persons, who reported respiratory and systemic symptoms following exposure to the tile-coating product, were clinically examined. The product was analysed chemically and furthermore, the exposure scenario was reconstructed using a climate chamber and the toxicological properties of the product were studied using in vivo and by in vitro surfactometry. RESULTS: The symptoms developed within few hours and included coughing, tachypnoea, chest pain, general malaise and fever. The physical examination revealed perihilar lung infiltrates on chest radiograph and reduced blood oxygen saturation. The acute symptoms resolved gradually within 1-3 days and no delayed symptoms were observed. By means of mass spectrometry and X-ray spectroscopy, it was shown that the product contained non-fluorinated alkylsiloxanes. The exposure conditions in the supermarket were reconstructed under controlled conditions in a climate chamber and particle and gas exposure levels were monitored over time allowing estimation of human exposure levels. Mice exposed to the product developed symptoms of acute pulmonary toxicity in a concentration-and time-dependent manner. The symptoms of acute pulmonary toxicity likely resulted from inhibition of the pulmonary surfactant function as demonstrated by in vitro surfactometry. Among these patients only a partial association between the level of exposure and the degree of respiratory symptoms was observed, which could be because of a high inter-individual difference in sensitivity and time-dependent changes in the chemical composition of the aerosol. CONCLUSION: Workers need to cautiously apply surface coating products because the contents can be highly toxic through inhalation, and the aerosols can disperse to locations remote from the worksite and affect bystanders.


Subject(s)
Inhalation Exposure/adverse effects , Lung/drug effects , Pulmonary Surfactant-Associated Proteins/antagonists & inhibitors , Siloxanes/toxicity , Administration, Inhalation , Adolescent , Adult , Aerosols , Animals , Chest Pain/chemically induced , Cough/chemically induced , Disease Models, Animal , Dose-Response Relationship, Drug , Female , Fever/chemically induced , Humans , Lung/pathology , Male , Mass Spectrometry , Mice , Mice, Inbred BALB C , Middle Aged , Siloxanes/administration & dosage , Siloxanes/chemistry , Time Factors , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL